Industry: Pharmaceuticals, Biotechnology
Aerie Pharmaceuticals is dedicated to the discovery and development of medical innovations in the field of ophthalmology. Based on intellectual property licensed from Duke University Medical Center, Aerie is developing a pipeline of proprietary products for the pharmaceutical treatment of glaucoma. Its lead clinical candidate, AR-101, is a second-generation glaucoma product with an expected superior efficacy and safety profile. AR-101 will enter clinical studies (Phase I/II) in 2006. Aerie’s pre-clinical programs focus on the development of novel outflow drugs to lower intra-ocular pressure. Aerie is headquartered in Research Triangle Park, North Carolina. ( www.aeriepharma.com )
Aerie Pharmaceuticals , Inc.
7020 Kit Creek Road, Suite 270 P.O. Box 12320
Research Triangle Park, North Carolina 27709
USA
Tel: (919) 313-9650
Fax: (919) 313-9651